We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
Read MoreHide Full Article
The Netherlands-based QIAGEN N.V. (QGEN - Free Report) , a global provider of Sample to Insight solutions, recently validated its GeneReader NGS System and published five new independent studies based on it at the Global Congress on Molecular Pathology in Berlin. We believe the favorable outcome will fortify the company’s position in the huge and growing global market of next-generation sequencing (NGS).
These studies confirm strong analytical performance of the world’s first complete Sample to Insight solution that gives access to the NGS platform in laboratories. Also, the validation of the GeneReader NGS System is a cost effective way for the laboratories to take advantage of.
Further, the studies show that the GeneReader NGS System is easy to use in laboratories with limited resources than the complex traditional NGS technology. These studies also demonstrated the efficacy of GeneReader System over other alternative systems, especially on a variety of cancer and sample types. In fact, the system offers unique benefits being the only fully integrated NGS workflow at present.
Of late, QIAGEN has been focusing on the expansion of its NGS platform. This is viewed as a major positive, taking the huge and untapped market potential of NGS into consideration. According to a recent report published by Markets and Markets, the global NGS market is expected to reach a worth of $12.45 billion by 2022, at an impressive CAGR of 20.5%. The latest studies with their favorable outcome are expected to help the company to tap into this rapidly growing market.
Recent NGS Development
The company is currently putting effort on enhancing the utility, efficiency and cost effectiveness of the GeneReader NGS System. To increase the use of oncology research applicants, QIAGEN will offer services to customers for the development of customized gene panels.
The gene panels have also been upgraded to incorporate the proprietary Digital NGS technology for accurate quantification and detection of variants in samples. If the company succeeds in its efforts, it may pose tough competition to the stalwarts in the niche industry.
QIAGEN has also reached its target of 55 to 60 placements of the GeneReader NGS System for oncology applications. In fact, the goal has been surpassed by at least 10%. Further, the company has acquired a privately held company, OmicSoft that is expected to compliment its bioinformatics portfolio.
Heska returned 249.22% in the last one year compared with the S&P 500’s gain of 15.03%.
The company reported a stellar four-quarter positive average earnings surprise of 291.54%.
Enzo Biochem surged 83.26% in the last one year compared with the S&P 500’s gain. Its four-quarter average earnings surprise is a positive 39.17%.
Galapagos gained 105.11% in the past one year, surpassing the S&P 500 mark. It delivered a positive average earnings surprise of 203.27% in the trailing four quarters.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access.Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
The Netherlands-based QIAGEN N.V. (QGEN - Free Report) , a global provider of Sample to Insight solutions, recently validated its GeneReader NGS System and published five new independent studies based on it at the Global Congress on Molecular Pathology in Berlin. We believe the favorable outcome will fortify the company’s position in the huge and growing global market of next-generation sequencing (NGS).
These studies confirm strong analytical performance of the world’s first complete Sample to Insight solution that gives access to the NGS platform in laboratories. Also, the validation of the GeneReader NGS System is a cost effective way for the laboratories to take advantage of.
Further, the studies show that the GeneReader NGS System is easy to use in laboratories with limited resources than the complex traditional NGS technology. These studies also demonstrated the efficacy of GeneReader System over other alternative systems, especially on a variety of cancer and sample types. In fact, the system offers unique benefits being the only fully integrated NGS workflow at present.
Of late, QIAGEN has been focusing on the expansion of its NGS platform. This is viewed as a major positive, taking the huge and untapped market potential of NGS into consideration. According to a recent report published by Markets and Markets, the global NGS market is expected to reach a worth of $12.45 billion by 2022, at an impressive CAGR of 20.5%. The latest studies with their favorable outcome are expected to help the company to tap into this rapidly growing market.
Recent NGS Development
The company is currently putting effort on enhancing the utility, efficiency and cost effectiveness of the GeneReader NGS System. To increase the use of oncology research applicants, QIAGEN will offer services to customers for the development of customized gene panels.
The gene panels have also been upgraded to incorporate the proprietary Digital NGS technology for accurate quantification and detection of variants in samples. If the company succeeds in its efforts, it may pose tough competition to the stalwarts in the niche industry.
QIAGEN has also reached its target of 55 to 60 placements of the GeneReader NGS System for oncology applications. In fact, the goal has been surpassed by at least 10%. Further, the company has acquired a privately held company, OmicSoft that is expected to compliment its bioinformatics portfolio.
Zacks Rank & Key Picks
Currently, QIAGEN carries a Zacks Ranks #3 (Hold). Better-ranked stocks in the broader Medical - Biomedical and Genetics space include Heska Corporation , Enzo Biochem, Inc. (ENZ - Free Report) and Galapagos NV (GLPG - Free Report) . While Heska sports a Zacks Rank #1 (Strong Buy), Enzo Biochem and Galapagos carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska returned 249.22% in the last one year compared with the S&P 500’s gain of 15.03%.
The company reported a stellar four-quarter positive average earnings surprise of 291.54%.
Enzo Biochem surged 83.26% in the last one year compared with the S&P 500’s gain. Its four-quarter average earnings surprise is a positive 39.17%.
Galapagos gained 105.11% in the past one year, surpassing the S&P 500 mark. It delivered a positive average earnings surprise of 203.27% in the trailing four quarters.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access.Click here for Zacks' private trades >>